Aclaris Therapeutics
ACRS
81 hedge funds and large institutions have $31.4M invested in Aclaris Therapeutics in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 29 reducing their positions, and 17 closing their positions.
4% less funds holding
Funds holding: 84 → 81 (-3)
16% less ownership
Funds ownership: 86.29% → 70.29% (-16%)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
28% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 29
60% less capital invested
Capital invested by funds: $78M → $31.4M (-$46.6M)
98% less call options, than puts
Call options by funds: $1K | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$2.38M |
| 2 |
BC
Broadfin Capital
New York
|
+$2.3M |
| 3 |
Morgan Stanley
New York
|
+$2.21M |
| 4 |
Renaissance Technologies
New York
|
+$1.8M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$8.72M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$8.42M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.61M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.65M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.29M |
ACRS Hedge Fund Activity: Q3 2019 in Review
81 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2019, worth a combined $31.4M — down 60% from $78M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ACRS and 14 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 21 added.
The largest buyer was Man Group, adding an estimated $2.38M. The largest seller was Deerfield Management, exiting entirely with an estimated $8.72M sold.
- 81 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2019, down from 84 in Q2 2019.
- Funds reported $31.4M of Aclaris Therapeutics stock for Q3 2019, down 60% quarter-over-quarter.
- 14 funds opened new Aclaris Therapeutics positions in Q3 2019 and 17 closed out, a net change of -3 holders.
- The largest Aclaris Therapeutics buyer in Q3 2019 was Man Group, an estimated $2.38M added.
- The largest Aclaris Therapeutics seller in Q3 2019 was Deerfield Management, an estimated $8.72M sold.
Based on aggregated 13F filings for Q3 2019.